AYVAKIT® (avapritinib) is an FDA-approved treatment for adults with Advanced Systemic Mastocytosis (Advanced SM). Limitations of Use: AYVAKIT (avapritinib) is not recommended for the treatment of patients with AdvSM with platelet counts of <50 x 109/L.
During this program, you will hear from an expert who will discuss the following topics:
- Introduction to Advanced Systemic Mastocytosis (Advanced SM)
- Overview of AYVAKIT Prescribing Information, including clinical trial data, safety information, and dosing recommendations
- Hypothetical patient cases based on clinical trial experience
AYVAKIT: The only targeted therapy FDA-approved for adults with Advanced SM designed for potent and selective inhibition of KIT D816V1
Presented (on behalf of Blueprint Medicines) by:
Christopher Maisel, MD
Texas Oncology, PA
Tuesday, November 01, 2022, 06:00 PM CDT
Capital Grille, 500 Crescent Court, Ste 135 (on Maple St.), Dallas, TX, 75201
To RSVP attendees can text me 214-998-4848 or email me dlafond@blueprintmedicines.com. I will need first/last name, clinic/hospital location of work, and license #.
Attendees must be currently directly involved in patient care in a clinic or hospital setting. I am not allowed to have those now working on the industry side attend my events for compliance purposes.
This is not a chapter meeting.11_1_22_Ayvakit_Branded_Speaker_Program_PDF_Invitation.pdf